tbuckley/cabot-search huggingface dataset:
Abstract 13806: Enhanced Atrial Automaticity Causes Ca Triggered Atrial Fibrillation in a Casq2-linked CPVT Mouse Model
Authors: Michela Faggioni, Raghav Venkataraman, Franz Baudenbacher, Bjorn C Knollmann
Journal: Circulation (2012)

Introduction Patients affected by catecholaminergic polymorphic ventricular tachycardia (CPVT), a familiar arrhythmogenic disorder, exhibit an increased risk for atrial fibrillation (AF). Although ...
Abstract 1326: Electrocardiographic Q-waves in the Healthy Population is Associated With Increased Risk of Heart Disease and Mortality: Results From the 4th Copenhagen City Heart Study
Authors: Rasmus Mogelvang, Jan S Jensen, Merete Appleyard, Gorm B Jensen, Steen Z Abildstrom
Journal: Circulation (2009)

Background: Electrocardiographic Q-waves in the healthy population is usually interpreted as a former silent myocardial infarction. Objective: To determine the independent prognostic value of such ...
Effectiveness of mycophenolate mofetil in C3 glomerulonephritis
Authors: Cristina Rabasco, Teresa Cavero, Elena Román, Jorge Rojas-Rivera, Teresa Olea, Mario Espinosa, Virginia Cabello, Gema Fernández-Juarez, Fayna González, Ana Ávila, José María Baltar, Montserrat Díaz, Raquel Alegre, Sandra Elías, Monserrat Antón, Miguel Angel Frutos, Alfonso Pobes, Miguel Blasco, Francisco Martín, Carmen Bernis, Manuel Macías, Sergio Barroso, Alberto de Lorenzo, Gema Ariceta, Manuel López-Mendoza, Begoña Rivas, Katia López-Revuelta, José María Campistol, Santiago Mendizábal, Santiago Rodríguez de Córdoba, Manuel Praga
Journal: Kidney International (2015)
Abstract 20989: Coronary Artery Spasm and Prognosis in Patients on Optimal Chronic Antispasmodic Therapy
Authors: Argyrios Ntalianis, Puymirat Etienne, Micaela Conte, Aaron Peace, Fabio Mangiacapra, Olivier Muller, Catalina Trana, Guy R Heyndrickx, Emanuele Barbato, William Wijns
Journal: Circulation (2010)
Comparative data on quality of care and outcome are urgently needed
Authors: M. Harding
Journal: BMJ (1995)

nappy was being changed; there was a "crack," and he was distressed.In our view it is unwise to label these fractures as spontaneous, although the force required may be less than that needed to fracture well mineralised bones.A difficulty arises if a non-accidental injury has occurred: if the fracture has been accepted as spontaneous the child is left unprotected.Children with disability are at greater risk of abuse than their peers, and some of these fractures will be the result of abuse.23 Have Lingam and Joester considered why the school attended by the subjects of their reports apparently has such a high incidence of fracture of the femur?
Abstract P327: KIF6 Carrier Status in Asians Predicts Beneficial Response to Statins
Authors: Gordon Fung, Alberto F Aparicio, Alan Wu, Andrew Smith, Ivy Wong
Journal: Circulation (2012)

Introduction: This is a prospective study of kif6, a genetic biomarker of cardiovascular disease and efficacy for statin therapy, using retrospective analysis of cardiac history. We explored the association between kif6 and cardiovascular disease (CVD) events (ACS, atherosclerosis with PCI or CABG) as well as the frequency of kif6 in Asians. In previous studies, carriers of kif6 had a higher incidence of CVD than non-carriers. The identification of a patient’s kif6 status may have impact on the therapeutic approach to reduce CVD risk. Hypothesis: Kif6 carriers with no or low dosage of statins have a higher rate of cardiovascular disease and treatment with higher dose statins have significant reduction in their rate of CVD events. Methods: We enrolled 135 patients from UCSF to determine kif6 carrier status and a review of their cardiac history. We analyzed the associations between high (40mg) vs. low (&lt; 20 mg) in carriers and non-carriers and accounted for CVD events. For 11 patients, the statin dose at the time of their CVD event was unknown. Given the standard of care practice, this group was assigned to low statin. Result: Prevalence of kif6 mutation in Asians is 72%. Kif6-carriers with low/no statin have higher rates of CVD events (38%) compared to those on high dose statin (13%). Kif6-non carriers did not have significant reduction in CVD events with statin treatment. Study selection bias was a referral population from the community for secondary cardiovascular care at UCSF and small study size. However, enrollment is continuing. Other possible biases are presence of co-morbidities, e.g., smoking status, lifestyle habitus, Diabetes, and hypertension. Conclusion: This is the first prospective study looking at kif6 mutation prevalence and impact in Asians. The prevalence of kif6 mutation is high among Asians. Kif6-carrier is predictive of CVD events. There is definitive benefit of high-dose statin therapy for kif6-carriers with reduction in CVD events. There is no definitive benefit of statin therapy for non-carriers. Table Kif6-Carrier: (n= 97) Kif6-Non-carrier: (n=37) Low statin, no CVD event 46 15 Low statin, w/ CVD event 28 10 Total 74 25 Event rate 38% 40% High statin, no CVD event 20 9 High statin, w/ CVD event 3 3 Total 23 12 Event rate 13% 25% P-value 0.0468 0.5983
Targeted inhibition of the gatekeeper mutant T315I of Bcr-Abl by an Aurora kinase inhibitor
Authors: Michele Modugno, Elena Casale, Chiara Soncini, Pamela Rosettani, Alessio Graziano, Riccardo Colombo, Rosita Lupi, Luisa Rusconi, Roberto Tonani, Laura Gianellini, Daniele Fancelli, Patrizia Carpinelli, Alexander Cameron, Antonella Isacchi, Jurgen Moll
Journal: Cancer Research (2007)

3253   Imatinib, a tyrosine kinase inhibitor that blocks the catalytic activity of Bcr-Abl, is currently the first line therapeutic for patients with chronic myelogenous leukemia (CML) and Philadelphia (Ph) chromosome-positive acute lymphoblastic leukemia (ALL). However, many patients treated with imatinib develop resistance to therapy and the majority of relapses is due to point mutations in the kinase domain of Bcr-Abl. Second generation Bcr-Abl inhibitors, such as nilotinib and dasatinib, inhibit many of the imatinib-resistant mutations to various degrees, with the exception of the T315I mutation located in the gatekeeper position of the kinase domain. The clinical importance of T315I mutation, that accounts for ~20% of clinically observed mutations, is expected to increase in the future in CML and ALL patients since it will represent the major mechanism of resistance to first and/or second generation inhibitors.  In our drug development process, we developed PHA-739358, a targeted Aurora kinase inhibitor that shows significant crossreactivity against the Abl kinase. We present here data demonstrating that this compound is capable of inhibiting the wild type Abl as well as the most clinically frequent imatinib-resistant Abl mutants, comprising the T315I mutant. Inhibition is observed both in vitro and in cell line models and it is due to the ability of the inhibitor to bind with high affinity to the Abl kinase domain. Interestingly, increased activity and affinity has been observed against the T315I mutant. The analysis of the crystallographic structure of the active, phosphorylated T315I mutant kinase domain complexed with PHA-739358 indicates that the compound accomodates into the ATP-binding pocket avoiding the hydrophobic pocket and without making any steric clash with the isoleucine side chain of the mutated gatekeeper. Furthermore, favourable hydrophobic interaction between the inhibitor and the isoleucine side chain would explain the higher activity of the compound against the T315I with respect to the wild type protein and the other mutants.  Clinical trials using PHA-739358 to assess efficacy in CML and Ph-positive ALL patients who had resistance to imatinib, including patients bearing the T315I mutation, have been initiated. Since the number of patients with the T315I mutation is expected to increase in the future in patients treated with first and/or second generation inhibitors, PHA-739358 holds promise for treating this patient population.
Prevalence of the rabbit syndrome
Authors: R Yassa, S Lal
Journal: American Journal of Psychiatry (1986)

Among 266 chronic inpatients receiving neuroleptics, six of the 137 (4.4%) receiving neuroleptics alone and none of the 129 receiving concomitant anticholinergics manifested the rabbit syndrome. Procyclidine resolved the signs of all affected patients. The syndrome's potential prevalence remains unknown.
Abstract 22: Endothelial Nitric Oxide Synthase Activation by Nano-Polymer Polyethylene-Oxide is Dependent on Nanomolecule Size and Concentration
Authors: Arkady Uryash, Heng Wu, Jorge Bassuk, Jose A Adams
Journal: Circulation (2010)

Background:  Nanopolymers can integrate into the systemic circulation and modify characteristics of blood flow. Polyethylene oxide (PEO) nanopolymer reportedly affects vascular endothelium through modification of near wall shear stress. This leads to phosphorylation of Endothelial Nitric Oxide Synthase eNOS (S1177), eNOS dependent NO increase and cardioprotection from focal ischemia reperfusion injury.   Aim:  We investigated whether or not eNOS upregulation and phosphorylation produced by PEO nanopolymers is depedent on its molecular size and concentration.   Methods:  Human endothelial cells were cultured inside the silicon tubing (L200 mm ID5 mm) and perfused 2 hrs with PEO 1000, 2000, 5000 and 10000 kDa 50 ppm solution (vehicle in controls (CONT)) in DMEM with pulsatile flow of 300 mL/min and pulse rate of 80 bpm. Another group was perfused with 5000 kDa PEO solution at 10, 20, 50 and 100 ppm. Levels of eNOS, p-eNOS (S1177) and flow parameters were measured.   Results:  In cultures exposed to PEO nanopolymer under pulsatile flow we observed 1) Dose dependent increase of p-eNOS; 2) When applied at the same concentration nanopolymer of larger size produced higher increased in eNOS activation through phosphorylation; 3) p-eNOS changes in PEO experiments were significantly different from CONT.   Conclusions:  Nanopolymers produce additional shear stress on the vascular endothelium which stimulates upregulation and phosphorylation of eNOS which is proportional to size and concentration of PEO.These findings are important for optimisizing the clinical effects of stimulating the endothelium through nanopolymers, to improve outcomes from ischemia reperfusion injury.
Abstract 21518: Ischemic Human Heart Failure is Associated With Decreased Phosphorylation of Pyruvate Dehydrogenase and Triosephosphate Isomerase: Proteomic Evidence Supporting Carbohydrate Utilization Preference in the End-Stage Failing Ischemic Heart
Authors: Valentino Piacentino, J. Will Thompson, Erik J Soderblom, Matthew Foster, Virginia A Burns, Joseph G Rogers, Carmelo A Milano, M. Arthur Moseley, Dawn E Bowles
Journal: Circulation (2010)
BioCluster: Tool for Identification and Clustering of Enterobacteriaceae Based on Biochemical Data
Authors: Ahmed Abdullah, S.M. Sabbir Alam, Munawar Sultana, M. Anwar Hossain
Journal: Genomics Proteomics & Bioinformatics (2015)

Abstract Presumptive identification of different Enterobacteriaceae species is routinely achieved based on biochemical properties. Traditional practice includes manual comparison of each biochemical property of the unknown sample with known reference samples and inference of its identity based on the maximum similarity pattern with the known samples. This process is labor-intensive, time-consuming, error-prone, and subjective. Therefore, automation of sorting and similarity in calculation would be advantageous. Here we present a MATLAB-based graphical user interface (GUI) tool named BioCluster. This tool was designed for automated clustering and identification of Enterobacteriaceae based on biochemical test results. In this tool, we used two types of algorithms, i.e., traditional hierarchical clustering (HC) and the Improved Hierarchical Clustering (IHC), a modified algorithm that was developed specifically for the clustering and identification of Enterobacteriaceae species. IHC takes into account the variability in result of 1–47 biochemical tests within this Enterobacteriaceae family. This tool also provides different options to optimize the clustering in a user-friendly way. Using computer-generated synthetic data and some real data, we have demonstrated that BioCluster has high accuracy in clustering and identifying enterobacterial species based on biochemical test data. This tool can be freely downloaded at http://microbialgen.du.ac.bd/biocluster/.
BCR-ABL1-Like Cases In Pediatric Acute Lymphoblastic Leukemia: A Comparison Between COG/St. Jude and Dutch DCOG Signatures
Authors: Judith M. Boer, João R.M. Marchante, Martin A. Horstmann, Gabriele Escherich, William E. Evans, Rob Pieters, Monique L. Den Boer
Journal: Blood (2013)
Abstract 1656: Prognosis After Ventricular Fibrillation During First Myocardial Infarction
Authors: Jonas S De Jong, Roos F Marsman, José P Henriques, Arthur A Wilde, Lukas R Dekker
Journal: Circulation (2007)

Introduction : Based on data from the thrombolysis era high mortality rates are ascribed to survivors of primary ventricular fibrillation, i.e. VF within the first 48 hours of acute myocardial infarction (AMI). However, current guidelines do not advice ICD implantation if left ventricular function recovers well. We present new data from a large dataset of primary VF survivors treated with percutaneous coronary intervention (PCI). Methods : Multi-center case-control study with prospective follow-up. Consecutive patients with a first AMI and VF prior to PCI (cases, n =372) were compared with patients with a first AMI without VF (controls, n =305). Primary endpoint is survival &gt; 30 days. Results : Median follow up duration was 3.34 years for cases and 3.69 years for controls ( p = 0.015). VF occurred at a mean of 65 minutes after onset of chest pain and occurred out of hospital in 42.3%, in the ambulance in 23.4% and after hospital admission in 32.7% of cases. Median time to PCI was 160 mins in cases vs 180 mins in controls. All cause mortality &gt; 30 days was 5.9% for cases and 8.2% for controls. Cox regression analysis showed that survival was not influenced by VF. During follow-up 25 cases received an ICD against 3 in controls. Even if all ICD wearers were presumed dead, VF did not reach significance as a predictor for survival. Significant predictors for improved survival were: younger age ( p =0.013) and time to PCI ( p =0.027). Conclusion : VF during AMI does not predict survival in those who survive the first month. These VF survivors have an excellent prognosis with or without an ICD. This study underlines that primary VF by itself does not constitute an indication for ICD implantation.
Abstract 18136: Mechanical Circulatory Support for Failing Systemic Right Ventricle - A Viable Bridging Strategy to Transplant?
Authors: Ed Peng, John O’Sullivan, Massimo Griselli, David Crossland, Milind Chaudhari, Neil Wrightson, Tanveer Butt, Gareth Parry, Guy MacGowan, Stephan Schueler, Asif Hasan
Journal: Circulation (2013)

BACKGROUND: The morphological right ventricle in the systemic position is associated with late failure and cardiac transplantation becomes the only treatment option. In the face of declining heart donor, the role of left ventricular assist device (VAD) as a bridge to transplant is well established. However, there is only scarce experience of supporting failing systemic right ventricle (RV). METHODS: Between 1989 and 2013, a total of 21 adult patients (age 18 years and above) had heart transplant in our institution for systemic RV failure. Since our inception case to support failing systemic RV mechanically in 2009, a total of six adult patients (5 males, mean age 36 years; 4 post atrial switch, 2 ccTGA) had been supported (5 Heartware and 1 Berlin Heart). Concomitant systemic atrioventricular surgery was required in two patients. Indications for systemic RV-VAD were (i) bridge to transplant (n=2) (group BTT) and (ii) bridge to further decision in the presence of high transpulmonary gradient and/or high PRA (n=4) (group BTD). RESULTS: Early mortality (&lt; 30 days) was 16.7% (n=1). One further patient died in-hospital following non-cardiac procedure (day 62). Overall, median ICU stay was 6 days (range 5-8 days). Four patients were discharged home: three patients reported significant improvement in functional capacity and serial TPGs assessment showed significant improvement. In group BTT, 1 was transplanted (at day 313 post-VAD). In group BTD, 1 patient was transplanted (day 685), one has on-going support (currently 375 days), and one died (day 232, sepsis and multi-organ failure). Three patients (50%) had cerebrovascular events (3, 4, 15 months post-VAD) with satisfactory recovery and one had recurrent bleeding episodes. One patient required further surgery (aortic valve replacement and device replacement due to thrombosis). Survival at transplant was 100% for those with VAD (n=2) (vs 89.5% for those without VAD support, n=17/19). CONCLUSION: The use of ventricular assist device to support failing systemic RV is a viable strategy to bridge for transplant or further assessment. Neurological event, albeit with satisfactory recovery, remains a significant morbidity.
Abstract 3266: Effects of Calcification and Stenting on Diagnostic Accuracy in the Evaluation of Coronary Artery Disease by 64 Slice Computed Tomography
Authors: Brian Seeck, Michael Barry, Joseph Craft, Donna C Lesniak, Bhalla Sanjeev, John M Lasala, Robert J Gropler, Pamela K Woodard
Journal: Circulation (2006)
Abstract 16082: Reversal of Ischemic Cardiomyopathy With Sca1+ Stem Cell Genetically Modified for Multiple Therapeutic Growth Factors Expression
Authors: Ning Li, Muhammad Ashraf, Shujia Jiang, Khawaja H Haider
Journal: Circulation (2011)

Background: We hypothesized that a combined approach involving Sca1+ bone marrow stem cells as carriers of multiple therapeutic genes will be more effective in preservation of heart function after ...
Abstract 810: Recruitment of the Inflammatory Subset of Monocytes to Sites of Ischemia Induces Angiogenesis in a Monocyte Chemoattractant Protein-1 Dependent Fashion
Authors: Ben Capoccia, Alyssa Gregory, Daniel Link
Journal: Circulation (2007)

Our lab has previously shown that mobilization of monocytes from the bone marrow to the blood by G-CSF and/or AMD3100 administration stimulated angiogenesis and enhanced revascularization following the induction of hindlimb ischemia in mice. Recent data suggest that monocytes can be divided into two distinct subsets based upon the expression of the fractalkine receptor CX3CR1. The inflammatory subset of monocytes express low levels of CX3CR1 but high levels of CCR2 and Gr-1. In contrast, the resident subset of monocytes express high levels of CX3CR1 but no CCR2 or Gr-1. Using transgenic mice expressing GFP under the control of the 2.1kb CX3CR1 promoter, we sorted inflammatory and resident monocytes and adoptively transferred them into mice 24 hours after the induction of hindlimb ischemia. Whereas inflammatory monocytes markedly improved revascularization, no effect was observed with resident monocytes. These data suggest that the inflammatory monocyte subset may be an attractive cell population to study in the therapeutic setting. The mechanism by which monocytes stimulate angiogenesis at sites of inflammation is not fully understood. Herein, we show that adoptively transferred CFSE-labeled monocytes are rapidly and specifically recruited from the blood to the ischemic hindlimb. These recruited donor monocytes induce a massive secondary recruitment of host monocytes that is associated with local production of MCP-1. To further explore the role of MCP-1 in this process, we repeated these adoptive transfer experiments in MCP-1 −/ − mice. Adoptive transfer of wild type monocytes into wild type mice markedly improved revascularization while no angiogenic effect was observed after adoptive transfer into MCP-1 −/ − mice. Moreover, whereas recruitment of adoptively transferred CFSE-labeled monocytes into the ischemic limb in MCP-1 −/ − mice was normal, the induction of MCP-1 expression and secondary recruitment of endogenous monocytes from the blood was significantly attenuated. Furthermore, MCP-1 −/ − mice showed no enhancement of angiogenesis following mobilization with G-CSF and AMD3100. These data suggest that MCP-1 plays a key role in the inflammatory angiogenic response by recruiting host monocytes from the blood into the ischemic tissue.
Abstract 19030: Apolipoprotein C-III is Significantly Reduced by Prescription Omega-3 Free Fatty Acids (Epanova) in Patients with Severe Hypertriglyceridemia and Changes Correlate with Increases in LDL-C: A Sub-analysis of the EVOLVE trial
Authors: Daniel J Rader, Richard L Dunbar, Kevin C Maki, Terry A Jacobson, Douglas Kling, Michael H Davidson
Journal: Circulation (2012)

Background: Apolipoprotein C-III (apoC-III) inhibits lipoprotein lipase activity and hepatic uptake of triglyceride-rich lipoproteins. Elevated levels of apoC-III have been found to be an independent predictor for CHD risk and genetically reduced apoC-III is associated with protection from CHD, making apoC-III a therapeutic target. Omega-3 fatty acid formulations containing docosahexaenoic acid (DHA) have been shown to increase LDL-C in patients with severe hypertriglyceridemia (HTG). Clinical data suggest that eicosapentaenoic acid (EPA) alone, which lowers triglycerides to a similar extent as EPA + DHA, does not raise LDL-C, but also fails to lower apoC-III. Materials: The EVOLVE trial evaluated 2, 3, and 4 g/d of a novel omega-3 free-fatty acid (FFA) formulation containing both EPA + DHA compared with 4 g/d of olive oil. In 399 patients with severe HTG we evaluated the effects on plasma apoC-III levels and the correlations between change in apoC-III and change in plasma lipids (TG, LDL-C) after 12-weeks of therapy. Results: Epanova 2, 3, and 4 g/d produced significant median reductions in apoC-III by 9 (p=0.02), 13 (p=0.006), and 15% (p&lt;0.001), respectively, compared to olive oil (+5%). Epanova produced significant (p&lt;0.001) median reductions in triglycerides (TG) of 26, 22, and 31%, respectively, compared to 10% for olive oil, and significant (p&lt;0.001) median increases in LDL-C of 21, 16, 26%, respectively, compared to 10% for olive oil. There was a significant positive correlation between percent changes in apoC-III and triglycerides (r=0.603, p&lt;0.001) and a significant negative correlation between percent changes in apoC-III and LDL-C concentrations (r=-0.28, p&lt;0.001). Conclusion: A novel omega-3 FFA formulation containing both EPA and DHA significantly lowered apoC-III levels in addition to reducing TG levels. An increase in LDL-C correlated with the reduction in apoC-III. Since EPA alone does not appear to lower apoC-III, these results support the hypothesis that DHA has specific effects in lowering apoC-III and that the mechanism by which DHA increases LDL-C may be related to its effect to lower apo CIII.